Astrazeneca Plc $AZN Shares Acquired by Abel Hall LLC

Abel Hall LLC raised its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 108.8% during the third quarter, HoldingsChannel.com reports. The firm owned 6,276 shares of the company’s stock after buying an additional 3,270 shares during the period. Abel Hall LLC’s holdings in Astrazeneca were worth $1,013,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Triumph Capital Management boosted its position in shares of Astrazeneca by 32.6% in the 3rd quarter. Triumph Capital Management now owns 252 shares of the company’s stock worth $41,000 after purchasing an additional 62 shares in the last quarter. Riversedge Advisors LLC grew its stake in Astrazeneca by 2.9% during the 3rd quarter. Riversedge Advisors LLC now owns 2,347 shares of the company’s stock worth $379,000 after buying an additional 67 shares during the last quarter. Veery Capital LLC grew its stake in Astrazeneca by 3.9% during the 3rd quarter. Veery Capital LLC now owns 1,857 shares of the company’s stock worth $300,000 after buying an additional 70 shares during the last quarter. Signal Advisors Wealth LLC increased its position in Astrazeneca by 2.7% during the 3rd quarter. Signal Advisors Wealth LLC now owns 2,778 shares of the company’s stock valued at $448,000 after buying an additional 72 shares in the last quarter. Finally, Rosenberg Matthew Hamilton increased its position in Astrazeneca by 3.8% during the 3rd quarter. Rosenberg Matthew Hamilton now owns 2,129 shares of the company’s stock valued at $344,000 after buying an additional 78 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Performance

Shares of NYSE:AZN traded down $1.38 on Monday, hitting $164.03. 2,322,055 shares of the company were exchanged, compared to its average volume of 2,812,117. The firm has a market capitalization of $254.40 billion, a P/E ratio of 24.52, a price-to-earnings-growth ratio of 1.40 and a beta of 0.27. The company has a current ratio of 0.89, a quick ratio of 0.67 and a debt-to-equity ratio of 0.47. Astrazeneca Plc has a 1-year low of $153.41 and a 1-year high of $212.71. The stock’s 50 day moving average price is $162.16 and its 200 day moving average price is $175.96.

Astrazeneca (NYSE:AZN) last released its earnings results on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.13. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%. The firm had revenue of $15.38 billion for the quarter, compared to the consensus estimate of $15.44 billion. During the same period in the prior year, the firm earned $2.17 EPS. The firm’s revenue was up 6.4% on a year-over-year basis. Sell-side analysts predict that Astrazeneca Plc will post 9.38 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on AZN. The Goldman Sachs Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Wall Street Zen lowered Astrazeneca from a “buy” rating to a “hold” rating in a research note on Sunday, October 11th. Zacks Research upgraded Astrazeneca from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 13th. Deutsche Bank Aktiengesellschaft upgraded shares of Astrazeneca from a “sell” rating to a “hold” rating in a report on Tuesday, September 15th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Fifteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Astrazeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of $206.67.

Astrazeneca Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.